Skip to main content
. 2013 Mar 11;31(13):1662–1668. doi: 10.1200/JCO.2012.45.9453

Fig 2.

Fig 2.

(A) Progression-free survival (PFS) according to random assignment groups. (B) Overall survival according to random assignment groups. (C) PFS of patients in second complete response according to random assignment groups. (D) PFS of patients with chemotherapy-sensitive relapse according to random assignment groups. B-BEAM, iodine-131 tositumomab plus carmustine, etoposide, cytarabine, and melphalan; R-BEAM, rituximab plus carmustine, etoposide, cytarabine, and melphalan.